Terms: = Skin cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
22 results:
1. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM
Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983
[TBL] [Abstract] [Full Text] [Related]
2. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
[TBL] [Abstract] [Full Text] [Related]
3. Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
Biteghe FAN; Padayachee E; Davids LM; Chalomie NET; Ndong JC; Barth S
J Photochem Photobiol B; 2020 Oct; 211():111982. PubMed ID: 32866820
[TBL] [Abstract] [Full Text] [Related]
4. Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris.
Jarocka-Karpowicz I; Biernacki M; Wroński A; Gęgotek A; Skrzydlewska E
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32121131
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
[TBL] [Abstract] [Full Text] [Related]
6. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
[TBL] [Abstract] [Full Text] [Related]
7. Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.
Al-Shammari AH; Masuo Y; Fujita KI; Yoshikawa Y; Nakamichi N; Kubota Y; Sasaki Y; Kato Y
J Pharm Sci; 2019 Jun; 108(6):2173-2179. PubMed ID: 30685396
[TBL] [Abstract] [Full Text] [Related]
8. Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Mohammad AS; Parrish KE; Mladek AC; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2019 Mar; 368(3):446-461. PubMed ID: 30622172
[TBL] [Abstract] [Full Text] [Related]
9. A Proof-of-Concept Study to Inhibit abcg2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
[TBL] [Abstract] [Full Text] [Related]
10. In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp).
Chakraborty R; Gupta H; Rahman R; Hasija Y
Comput Biol Chem; 2018 Dec; 77():430-441. PubMed ID: 30181081
[TBL] [Abstract] [Full Text] [Related]
11. Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.
Marzagalli M; Moretti RM; Messi E; Marelli MM; Fontana F; Anastasia A; Bani MR; Beretta G; Limonta P
Sci Rep; 2018 Jan; 8(1):587. PubMed ID: 29330434
[TBL] [Abstract] [Full Text] [Related]
12. Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
Basu R; Baumgaertel N; Wu S; Kopchick JJ
Horm Cancer; 2017 Jun; 8(3):143-156. PubMed ID: 28293855
[TBL] [Abstract] [Full Text] [Related]
13. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Biteghe FN; Davids LM
J Photochem Photobiol B; 2017 Jan; 166():18-27. PubMed ID: 27852006
[TBL] [Abstract] [Full Text] [Related]
14. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract] [Full Text] [Related]
15. Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells.
Roudi R; Ebrahimi M; Sabet MN; Najafi A; Nourani MR; Fomeshi MR; Samadikuchaksaraei A; Shariftabrizi A; Madjd Z
Future Oncol; 2015; 11(17):2383-93. PubMed ID: 26285774
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of ABC transporters in human skin.
Osman-Ponchet H; Boulai A; Kouidhi M; Sevin K; Alriquet M; Gaborit A; Bertino B; Comby P; Ruty B
Drug Metabol Drug Interact; 2014; 29(2):91-100. PubMed ID: 24558228
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of ATP-binding cassette transporter abcg2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract] [Full Text] [Related]
18. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Liu G; Cheng D; Ding K; Le Maitre A; Liu N; Patel D; Chen Z; Seymour L; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Feb; 7(2):316-22. PubMed ID: 22237259
[TBL] [Abstract] [Full Text] [Related]
20. CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.
Taghizadeh R; Noh M; Huh YH; Ciusani E; Sigalotti L; Maio M; Arosio B; Nicotra MR; Natali P; Sherley JL; La Porta CA
PLoS One; 2010 Dec; 5(12):e15183. PubMed ID: 21203549
[TBL] [Abstract] [Full Text] [Related]
[Next]
